Vaccine-induced COVID-19 mimicry syndrome.
COVID-19
/ prevention & control
COVID-19 Vaccines
/ adverse effects
ChAdOx1 nCoV-19
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ etiology
Humans
Pandemics
SARS-CoV-2
Sinus Thrombosis, Intracranial
/ etiology
Spike Glycoprotein, Coronavirus
/ genetics
Syndrome
Thrombocytopenia
/ etiology
Vaccination
/ adverse effects
Vaccines, DNA
/ adverse effects
Venous Thrombosis
/ etiology
RNA
SARS-CoV-2
cell biology
human
infectious disease
microbiology
splice variants
splicing
thrombosis
vaccines
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
27 01 2022
27 01 2022
Historique:
received:
25
10
2021
accepted:
21
01
2022
pubmed:
28
1
2022
medline:
25
2
2022
entrez:
27
1
2022
Statut:
epublish
Résumé
To fight the COVID-19 pandemic caused by the RNA virus SARS-CoV-2, a global vaccination campaign is in progress to achieve the immunization of billions of people mainly with adenoviral vector- or mRNA-based vaccines, all of which encode the SARS-CoV-2 Spike protein. In some rare cases, cerebral venous sinus thromboses (CVST) have been reported as a severe side effect occurring 4-14 days after the first vaccination and were often accompanied by thrombocytopenia. Besides CVST, splanchnic vein thromboses (SVT) and other thromboembolic events have been observed. These events only occurred following vaccination with adenoviral vector-based vaccines but not following vaccination with mRNA-based vaccines. Meanwhile, scientists have proposed an immune-based pathomechanism and the condition has been coined vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe an unexpected mechanism that could explain thromboembolic events occurring with DNA-based but not with RNA-based vaccines. We show that DNA-encoded mRNA coding for Spike protein can be spliced in a way that the transmembrane anchor of Spike is lost, so that nearly full-length Spike is secreted from cells. Secreted Spike variants could potentially initiate severe side effects when binding to cells via the ACE2 receptor. Avoiding such splicing events should become part of a rational vaccine design to increase safety of prospective vaccines.
Identifiants
pubmed: 35084333
doi: 10.7554/eLife.74974
pii: 74974
pmc: PMC8846585
doi:
pii:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines, DNA
0
spike protein, SARS-CoV-2
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022, Kowarz et al.
Déclaration de conflit d'intérêts
EK, LK, MK, PS, PL, JR, SB, TE, SK, RM No competing interests declared
Références
Mol Ther. 2011 Aug;19(8):1547-57
pubmed: 21556053
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Ann Diagn Pathol. 2021 Apr;51:151682
pubmed: 33360731
Intern Med. 2002 Mar;41(3):211-5
pubmed: 11929183
Hum Gene Ther. 2020 Oct;31(19-20):1100-1113
pubmed: 32552215
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926098
PLoS One. 2012;7(7):e40385
pubmed: 22808149
Cells. 2020 Jul 09;9(7):
pubmed: 32660065
Circ Res. 2021 Apr 30;128(9):1323-1326
pubmed: 33784827
Annu Rev Biochem. 2015;84:291-323
pubmed: 25784052
Hum Gene Ther. 2000 Oct 10;11(15):2105-16
pubmed: 11044912
Bioinformatics. 2018 Dec 15;34(24):4180-4188
pubmed: 29931149
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
J Virol. 1996 Nov;70(11):7498-509
pubmed: 8892868
Mol Ther. 2005 Jan;11(1):19-25
pubmed: 15585402
Biotechnol J. 2015 Apr;10(4):647-53
pubmed: 25650551
Gene. 2006 Feb 1;366(2):219-27
pubmed: 16226402
Front Immunol. 2020 Jul 10;11:1212
pubmed: 32754149
Blood. 2021 Oct 7;138(14):1269-1277
pubmed: 34280256
Adv Biol Regul. 2020 Aug;77:100741
pubmed: 32773102
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Genome Med. 2021 Mar 15;13(1):43
pubmed: 33722288
PLoS Pathog. 2020 Dec 7;16(12):e1009128
pubmed: 33284859
J Immunol. 1969 Nov;103(5):1089-95
pubmed: 4981794
Am J Blood Res. 2011;1(1):1-12
pubmed: 22432062